US sales of pet medications are surging,
with continued double-digit gains predicted for the foreseeable
future as all of the world's largest pharmaceutical companies
move full-force into the market, adapting human technologies
and developing pet-specific ones, according to the new Packaged
Facts report
The U.S. Market for Pet Medications: Prescription and Over the
Counter Remedies as Consumer Products.
Also driving market growth are the aging
pet population and rising rates of pet overweight/obesity,
which are spurring demand for a myriad new product types. With
a unique "cross-market" focus examining trends in both the
veterinary (pharmaceutical) and retail (OTC) sectors, the
report analyzes the market for dog and cat medications, with a
particular focus on products marketed directly to consumers in
areas including antiparasitics, pain management, mood
disorders, overweight/obesity, cognitive dysfunction and oral
care. Companies profiled include Pfizer,
Intervet-Schering, Bayer, Fort Dodge, Novartis, Central Garden
& Pet, Hartz and Sergeant's. The retail performance of pet
medication marketers and brands is evaluated using IRI
InfoScan Review
data and uniquely cross-tabulated Simmons consumer survey data
provide penetrating insight into pet medication consumer usage
rates, demographics and psychographics.